Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169


Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis.

Mills HL, Cohen T, Colijn C.

Sci Transl Med. 2013 Apr 10;5(180):180ra49. doi: 10.1126/scitranslmed.3005260.


Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations.

Cohen T, Lipsitch M, Walensky RP, Murray M.

Proc Natl Acad Sci U S A. 2006 May 2;103(18):7042-7. Epub 2006 Apr 21.


Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure.

Mills HL, Cohen T, Colijn C.

J R Soc Interface. 2011 Oct 7;8(63):1510-20. doi: 10.1098/rsif.2011.0160. Epub 2011 Apr 20.


Response to comment on "Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis".

Mills HL, Cohen T, Colijn C.

Sci Transl Med. 2013 Sep 25;5(204):204lr4. doi: 10.1126/scitranslmed.3007442.


The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study.

Hermans SM, Grant AD, Chihota V, Lewis JJ, Vynnycky E, Churchyard GJ, Fielding KL.

BMC Med. 2016 Mar 23;14:45. doi: 10.1186/s12916-016-0589-3.


Isoniazid preventive therapy and risk for resistant tuberculosis.

Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD.

Emerg Infect Dis. 2006 May;12(5):744-51. Review.


Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials.

Ayele HT, Mourik MS, Debray TP, Bonten MJ.

PLoS One. 2015 Nov 9;10(11):e0142290. doi: 10.1371/journal.pone.0142290. eCollection 2015. Review.


Comment on "Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis".

Ukwaja KN.

Sci Transl Med. 2013 Sep 25;5(204):204le3. doi: 10.1126/scitranslmed.3006386.


Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting.

van Halsema CL, Fielding KL, Chihota VN, Russell EC, Lewis JJ, Churchyard GJ, Grant AD.

AIDS. 2010 Apr 24;24(7):1051-5. doi: 10.1097/QAD.0b013e32833849df.


Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues.

Aït-Khaled N, Alarcon E, Bissell K, Boillot F, Caminero JA, Chiang CY, Clevenbergh P, Dlodlo R, Enarson DA, Enarson P, Ferroussier O, Fujiwara PI, Harries AD, Heldal E, Hinderaker SG, Kim SJ, Lienhardt C, Rieder HL, Rusen ID, Trébucq A, Van Deun A, Wilson N.

Int J Tuberc Lung Dis. 2009 Aug;13(8):927-35.


Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature.

Briggs MA, Emerson C, Modi S, Taylor NK, Date A.

J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3:S297-305. doi: 10.1097/QAI.0000000000000497. Review.


Interventions to improve delivery of isoniazid preventive therapy: an overview of systematic reviews.

Adams LV, Talbot EA, Odato K, Blunt H, Steingart KR.

BMC Infect Dis. 2014 May 21;14:281. doi: 10.1186/1471-2334-14-281. Review.


Tuberculosis preventive therapy: an underutilised strategy to reduce individual risk of TB and contribute to TB control.

Churchyard GJ, Chaisson RE, Maartens G, Getahun H.

S Afr Med J. 2014 Apr 16;104(5):339-43. doi: 10.7196/samj.8290. Review.


Implementing an isoniazid preventive therapy program for people living with HIV in Thailand.

Danyuttapolchai J, Kittimunkong S, Nateniyom S, Painujit S, Klinbuayaem V, Maipanich N, Maokamnerd Y, Pevzner E, Whitehead S, Kanphukiew A, Monkongdee P, Martin M.

PLoS One. 2017 Sep 26;12(9):e0184986. doi: 10.1371/journal.pone.0184986. eCollection 2017.


Tuberculosis screening and isoniazid preventive therapy implementation: a Brazilian experience.

Swaminathan S, Chandrasekaran P.

Expert Rev Anti Infect Ther. 2014 Mar;12(3):289-92. doi: 10.1586/14787210.2014.880338. Epub 2014 Jan 23.


Bacillus Calmette-Guérin and isoniazid preventive therapy protect contacts of patients with tuberculosis.

Zelner JL, Murray MB, Becerra MC, Galea J, Lecca L, Calderon R, Yataco R, Contreras C, Zhang Z, Grenfell BT, Cohen T.

Am J Respir Crit Care Med. 2014 Apr 1;189(7):853-9. doi: 10.1164/rccm.201310-1896OC.


Effect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: a retrospective cohort study.

Ayele HT, van Mourik MS, Bonten MJ.

BMC Infect Dis. 2015 Aug 13;15:334. doi: 10.1186/s12879-015-1089-3.


Implementation and evaluation of an isoniazid preventive therapy pilot program among HIV-infected patients in Vietnam, 2008-2010.

Trinh TT, Han DT, Bloss E, Le TH, Vu TT, Mai AH, Nguyen NV, Nguyen LT, Dinh SN, Whitehead S.

Trans R Soc Trop Med Hyg. 2015 Oct;109(10):653-9. doi: 10.1093/trstmh/trv074.


Thibela TB: design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa.

Fielding KL, Grant AD, Hayes RJ, Chaisson RE, Corbett EL, Churchyard GJ.

Contemp Clin Trials. 2011 May;32(3):382-92. doi: 10.1016/j.cct.2010.12.008. Epub 2010 Dec 28.


Supplemental Content

Support Center